Avalo Therapeutics Inc (NASDAQ: AVTX) kicked off on Monday, up 11.68% from the previous trading day, before settling in for the closing price of $15.11. Over the past 52 weeks, AVTX has traded in a range of $3.39-$19.41.
Healthcare Sector giant saw their annual sales surged by 56.49% over the last five years. While this was happening, its average annual earnings per share was recorded 67.90%. With a float of $15.19 million, this company’s outstanding shares have now reached $17.83 million.
Avalo Therapeutics Inc (AVTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Avalo Therapeutics Inc is 16.24%, while institutional ownership is 72.88%. The most recent insider transaction that took place on Nov 14 ’25, was worth 162,937. In this transaction Director of this company sold 11,367 shares at a rate of $14.33, taking the stock ownership to the 0 shares.
Avalo Therapeutics Inc (AVTX) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -2.74 earnings per share (EPS), lower than consensus estimate (set at 1.66) by -4.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.81 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 67.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.97% during the next five years compared to 56.49% growth over the previous five years of trading.
Avalo Therapeutics Inc (NASDAQ: AVTX) Trading Performance Indicators
Take a look at Avalo Therapeutics Inc’s (AVTX) current performance indicators. Last quarter, stock had a quick ratio of 14.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1610.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.73, a number that is poised to hit -1.53 in the next quarter and is forecasted to reach -5.83 in one year’s time.
Technical Analysis of Avalo Therapeutics Inc (AVTX)
Analysing the last 5-days average volume posted by the [Avalo Therapeutics Inc, AVTX], we can find that recorded value of 0.48 million was better than the volume posted last year of 0.19 million. As of the previous 9 days, the stock’s Stochastic %D was 43.10%.
During the past 100 days, Avalo Therapeutics Inc’s (AVTX) raw stochastic average was set at 82.94%, which indicates a significant increase from 58.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.37 in the past 14 days, which was higher than the 0.99 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.23, while its 200-day Moving Average is $8.38. Now, the first resistance to watch is $17.95. This is followed by the second major resistance level at $19.03. The third major resistance level sits at $20.52. If the price goes on to break the first support level at $15.38, it is likely to go to the next support level at $13.89. Should the price break the second support level, the third support level stands at $12.81.
Avalo Therapeutics Inc (NASDAQ: AVTX) Key Stats
The company with the Market Capitalisation of 306.01 million has total of 18,134K Shares Outstanding. Its annual sales at the moment are 440 K in contrast with the sum of -35,130 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -30,630 K.
